Targeted Treatment of Hematological Malignancy
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 165
Special Issue Editors
Interests: acute lymphoblastic leukemia; drug resistance; pre-clinical modelling; genomic analyses; precision medicine
2. Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia
Interests: myelofibrosis; myeloproliferative neoplasms; acute myeloid leukaemia; mutation-specific therapies; immunotherapy; CAR-T cell therapy
2. Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia
Interests: acute lymphoblastic leukemia; gene therapy; murine models; genomic predisposition; precision medicine
Interests: acute lymphoblastic leukemia; pre-clinical modelling; genomic analyses; precision medicine; functional genomics; microbiome
Special Issue Information
Dear Colleagues,
Our Special Issue on the Targeted Treatment of Hematological Malignancy aims to provide a comprehensive overview of the latest advancements and emerging trends in the field of hematology. The collection of articles in this Special Issue will focus on areas, such as novel targeted therapies and their efficacy in different malignancies, immunotherapeutic approaches for hematological malignancies, personalized treatment strategies, as well as diagnostic tools for assessing treatment responses.
We welcome original research articles, comprehensive reviews, and meta-analyses that provide valuable insights into the targeted treatment of hematological malignancies. However, please note that this Special Issue will not consider mini-reviews or case reports.
This Special Issue presents an excellent opportunity for researchers and clinicians to contribute to advanced targeted treatment options for hematological malignancies. We anticipate that the collection of articles in this Special Issue will provide valuable knowledge and pave the way for future breakthroughs in hematology.
We look forward to receiving your contributions and thank you for your support.
Dr. Laura Eadie
Dr. Chloe A.L. Thompson-Peach
Dr. Elyse C. Page
Prof. Dr. Deborah White
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- lymphoma
- multiple myeloma
- myelodysplastic syndromes
- chronic myeloid leukemia
- acute lymphoblastic leukemia
- acute myeloid leukemia
- non-Hodgkin lymphoma
- Hodgkin lymphoma
